Equities

Percheron Therapeutics Ltd

Percheron Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.10
  • Today's Change0.002 / 2.04%
  • Shares traded508.43k
  • 1 Year change+42.86%
  • Beta0.3442
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in AUD

The 3 analysts offering 12 month price targets for Percheron Therapeutics Ltd have a median target of 0.24, with a high estimate of 0.270 and a low estimate of 0.14. The median estimate represents a 140.00% increase from the last price of 0.10.
High170.0%0.270
Med140.0%0.24
Low40.0%0.14

Earnings history & estimates in AUD

Percheron Therapeutics Ltd reported annual 2024 losses of -0.014 per share on Aug 29, 2024.
Average growth rate+7.57%
More ▼

Revenue history & estimates in AUD

Antisense Therapeutics Limited had revenues for the full year 2024 of 2.97m. This was 670.91% above the prior year's results.
Average growth rate+11,423.05%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.